IVIM Health vs bmiMD: Tirzepatide Price and Terms Compared

IVIM Health and bmiMD at a glance

How to decide

If you expect to maintain at 10 mg or above, weight the higher tiers heavily — that is where you will spend most of the year. If your prescriber expects to hold you at 5 mg, the lower tiers matter more and the ranking may reverse.

Beyond price, the questions that actually differentiate programs are: is the compounding pharmacy named, is the prescriber named, does the quoted rate hold at renewal, and what happens if a cold-chain shipment fails. Our nine-point checklist covers all of them.

Which of these two fits which patient

bmiMD is the cheaper of the two over twelve months on our standard escalation, by $423. That gap is the starting point, not the answer — here is what each side offers that the other does not.

• Pick IVIM Health if cash-pay now with an insurance path later matters more to you than the price difference.
• Pick bmiMD if the lowest published per-month rate, if you can commit to a twelve-month term is the priority, and you want a price that does not move when your dose does.
• Neither, if you cannot get a straight answer about which pharmacy fills the prescription. That question outranks a $423 difference — see the verification walkthrough.

What each one publishes before you pay

Our disclosure score measures how much a program tells you up front — pricing at every dose, the pharmacy behind it, the terms. It is not a safety rating and not a recommendation, and the full formula and dataset are published so you can recompute it.

What this comparison deliberately leaves out

Service quality, shipping reliability and clinical depth are not scored here, because we do not hold measurements of them that we would defend in public. Both programs should be read alongside their full reviews and, where our sources disagree on price, the conflict notes on those pages.

IVIM Health vs bmiMD: where the money separates

A single annual figure hides when the gap opens. This is the same two programs tracked month by month through a first year, so you can see whether the difference is front-loaded during titration or accumulates quietly at maintenance.

By the end of month 8 the running difference has passed a full month of medication at bmiMD's maintenance rate. Across the year the gap reaches $423, roughly 13% of the larger program's twelve-month total and about 1.8 months of therapy at the cheaper rate.

Does IVIM Health vs bmiMD change at higher tirzepatide doses?

The ranking is dose-sensitive. At 5 mg IVIM Health is cheaper; by 15 mg the order has reversed and bmiMD is. If your prescriber expects to hold you low, that reversal is the whole decision.

IVIM Health and bmiMD plans, membership and prepaid terms

Only bmiMD publishes a discounted prepaid rate ($139 on its 12-month plan). IVIM Health does not, which means less commitment risk and less discount. If you are still establishing tolerance, the absence of a lock-in is worth something.

Membership fees are included in every figure above. IVIM Health charges $75 per month on top of medication. An advertised medication price that excludes this is not comparable to one that does not charge it at all, which is why our tables fold it in.

IVIM Health vs bmiMD on format and state availability

Both dispense in the same formats (injection), so format is not a deciding factor between these two.

Both publish comparable state coverage, so availability is unlikely to decide this for you — but confirm at checkout regardless, because service maps change without notice.

IVIM Health vs bmiMD: which discloses more

There is a real disclosure gap here: bmiMD scores 85/100 against 45/100 for IVIM Health. That is not a safety judgment — it measures how much each publishes before you pay. But a program that will not tell you which pharmacy fills your prescription is asking you to inject an unidentified preparation weekly, and that question outranks a $423 price difference.

Switching between IVIM Health and bmiMD

If you are already with IVIM Health and considering the move, the arithmetic is $423 over a year, or roughly 1.8 months of therapy at the cheaper program's maintenance rate. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that the new prescriber restarts titration rather than continuing you at your current dose. Ask about dose continuation in writing before you cancel anything, because a month at 2.5 mg is a month of lost progress that no price difference recovers.

IVIM Health vs bmiMD at every maintenance dose

The headline comparison assumes a 10 mg maintenance dose. Your prescriber may not land you there. This is the same comparison run at all six strengths, so you can find the row that matches your likely outcome rather than ours.

The answer flips at 7.5 mg. Below it IVIM Health costs less over twelve months; from there upward bmiMD does. If your prescriber has not yet decided your maintenance dose, this comparison genuinely has no single answer — and a flat-rate program is the hedge against that uncertainty.

IVIM Health vs bmiMD by what you are optimizing

• Lowest possible total cost: bmiMD, at $2,796 over a first year.
• Budget certainty: bmiMD, which holds one price at every strength.
• Verifiability before you pay: bmiMD (85/100 against 45/100).
• Avoiding a commitment: IVIM Health, which does not require a prepaid term for its published rate.
• Regulatory status: both dispense compounded preparations, which are not FDA-approved and are not reviewed by FDA before marketing.

IVIM Health vs bmiMD over three years

Tirzepatide behaves like maintenance therapy: the withdrawal evidence shows substantial regain after stopping, so the honest planning horizon is years rather than months. Held at a 10 mg maintenance dose, three years costs roughly $10,008 with IVIM Health and $8,388 with bmiMD — a difference of $1,620. That is the number worth deciding on, not the first invoice.

Neither figure should be treated as fixed. Pricing in this market has moved repeatedly, and programs rarely notify existing patients when a cheaper tier appears. Re-run this comparison annually at your actual maintenance dose.

IVIM Health vs bmiMD: what neither comparison table can tell you

Shipping reliability, how fast a clinician actually replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. These decide satisfaction more than price does, and we hold no measurements of them we would defend, so they are absent from every figure above rather than estimated. Read both program reviews and, if you can, ask a current patient of each.

The one proxy worth using is what each publishes before it has your money. A program that states its price at every dose, names its pharmacy and puts its cancellation terms in writing has already told you something about how it will behave when there is a problem — which is why the disclosure comparison above sits alongside the price comparison rather than beneath it.

Running this comparison again later

Both prices carry a verification date and both will change. Programs do not notify existing patients when a competitor drops below them, and several tracked programs have moved pricing more than once in the past year. Re-run this at your actual maintenance dose annually with the projector, and treat any figure older than a month as needing a re-check before you act on it.

IVIM Health vs bmiMD: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

IVIM Health vs bmiMD: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

IVIM Health vs bmiMD: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.